Joseph Michael Fitzgerald - 21 Feb 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
21 Feb 2023
Transactions value $
-$88,900
Form type
4
Filing time
22 Feb 2023, 15:54:46 UTC
Previous filing
21 Feb 2023
Next filing
17 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +3.9K +1.78% $0.00 222K 21 Feb 2023 Direct F1
transaction BSX Common Stock Tax liability -$88.9K -1.92K -0.87% $46.23 220K 21 Feb 2023 Direct
holding BSX Common Stock 68.1K 21 Feb 2023 By 401(k) F2
holding BSX Common Stock 4.34K 21 Feb 2023 By Child F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Deferred Stock Units Options Exercise $0 -3.9K -100% $0.00* 0 21 Feb 2023 Common Stock 3.9K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F4 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.